Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

395.11 +0.75 (+0.19%)
Streaming Delayed Price Updated: 9:49 AM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
 
Via Benzinga
3 Cash-Burning Stocks Walking a Fine Line
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even... 
Via StockStory
Topics Bankruptcy Economy
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again)
Via The Motley Fool
Topics Artificial Intelligence Energy World Trade
The Best Stocks to Invest $1,000 in Right Now
Via The Motley Fool
Topics Artificial Intelligence
10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
With just a little bit of a deeper look, these businesses are positioned for long-term growth. 
Via The Motley Fool
Motley Fool Co-Founder David Gardner Reviews Stock Picks
Via The Motley Fool
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
Via The Motley Fool
Topics Stocks
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
The Best Stocks to Invest $1,000 In Right Now
Via The Motley Fool
Topics Artificial Intelligence Government
Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EU
Vertex announced on Tuesday that eligible patients in Ireland, Denmark, and Germany will have access to Alyftrek shortly after receiving regulatory approval from the relevant authorities. 
Via Stocktwits
$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
How Do Investors Really Feel About Vertex Pharmaceuticals?
 
Via Benzinga
3 S&P 500 Stocks with Mounting Challenges
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Artificial Intelligence Stocks
Vertex Pharmaceuticals Unusual Options Activity
 
Via Benzinga
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Unpopular Stocks Facing Headwinds
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
Friday's session: gap up and gap down stock in the S&P500 index
Let's have a look at what is happening on the US markets on Friday. Below you can find the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
2 Growth Stocks to Buy and Hold for 10 Years
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 10 Analysts
 
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
1 Nasdaq 100 Stock for Long-Term Investors and 2 to Ignore
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or... 
Via StockStory
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It
Cathie Wood is bullish on biotech companies using gene sequencing, AI, and CRISPR tech to cure previously untreatable diseases. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS